Am. J. Respir. Crit. Care Med., Volume 160, Number 1, July 1999, 93-99

Lung Function and Sputum Characteristics of Patients with Severe Asthma During an Induced Exacerbation by Double-Blind Steroid Withdrawal

JOHANNES C. C. M.in`t VEEN, HERMELIJN H. SMITS, PIETER S. HIEMSTRA, AEILKO E. ZWINDERMAN, PETER J. STERK, and ELISABETH H. BEL

Departments of Pulmonology and Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands

Some patients with severe asthma are difficult to control and suffer from frequent exacerbations, whereas others remain stable with anti-inflammatory therapy. To investigate mechanisms of exacerbations, we compared 13 patients 20 to 51 yr of age (11 female, two male) with difficult-to-control asthma (two or more exacerbations during the previous year) and 15 patients 20 to 47 yr of age (13 female, two male) with severe but stable asthma (no exacerbations) after matching for sex, age, atopy, lung function, airway responsiveness, and medication. Exacerbations were induced by double-blind, controlled tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals. FEV₁, airway responsiveness for methacholine (PC₂₀MCh) and hypertonic saline (HYP slope), eosinophils and soluble markers (ECP, albumin, IL-6, IL-8) in induced sputum were assessed at baseline and during exacerbation (peak flow < 60% of personal best), or after 5 wk if no exacerbation occurred. Steroid tapering caused a decrease (mean ± SEM) in FEV₁ (12.1 ± 3.1% pred; p = 0.045), PC₂₀MCh (2.1 ± 0.4 doubling dose; p = 0.004) and HYP slope (1.7 ± 0.3 doubling dose; p = 0.001), and an increase in sputum eosinophils (10 ± 3%; p = 0.008) and soluble markers for the two groups combined, without significant differences between the groups. Patients with difficult-to-control asthma had more exacerbations than did the stable asthmatics during both steroid tapering (7 versus 2; p = 0.022) and corticosteroid treatment (6 versus 0; p = 0.003). Exacerbations during steroid treatment in the patients with difficult-to-control asthma were associated with a decrease in FEV₁ and PC₂₀MCh, but not in HYP slope or increase in sputum eosinophils. We conclude that tapering of inhaled corticosteroids induces a rapid, reversible flare-up of eosinophilic airway inflammation. Patients with difficult-to-control asthma may develop exacerbations despite treatment with inhaled corticosteroids, which appear to have an eosinophil-independent mechanism. This implies that assessment of the nature of exacerbations may contribute to improved treatment for these patients. in `t

This article has been cited by other articles:

				J. Belda, G. Margarit, C. Martinez, J. Bellido-Casado, P. Casan, M. Torrejon, M. Brufal, F. Rodriguez-Jerez, and J. Sanchis Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Eur. Respir. J., December 1, 2007; 30(6): 1143 - 1149. [Abstract] [Full Text] [PDF]

				K. Maneechotesuwan, S. Essilfie-Quaye, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated With Increased Sputum Interleukin-8 and Neutrophils Chest, July 1, 2007; 132(1): 98 - 105. [Abstract] [Full Text] [PDF]

				C. Brindicci, K. Ito, P. J. Barnes, and S. A. Kharitonov Differential Flow Analysis of Exhaled Nitric Oxide in Patients With Asthma of Differing Severity Chest, May 1, 2007; 131(5): 1353 - 1362. [Abstract] [Full Text] [PDF]

				H. K. Reddel and D. J. Barnes Pharmacological strategies for self-management of asthma exacerbations. Eur. Respir. J., July 1, 2006; 28(1): 182 - 199. [Abstract] [Full Text] [PDF]

				A. Foresi, B. Mastropasqua, A. Chetta, R. D'Ippolito, R. Testi, D. Olivieri, and A. Pelucchi Step-Down Compared to Fixed-Dose Treatment With Inhaled Fluticasone Propionate in Asthma Chest, January 1, 2005; 127(1): 117 - 124. [Abstract] [Full Text] [PDF]

				C M Salome, J D Leuppi, R Freed, and G B Marks Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation Thorax, December 1, 2003; 58(12): 1042 - 1047. [Abstract] [Full Text] [PDF]

				The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur. Respir. J., September 1, 2003; 22(3): 470 - 477. [Abstract] [Full Text] [PDF]

				G.F. Joos and B. O'Connor Indirect airway challenges Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068. [Abstract] [Full Text] [PDF]

				Leader of the Working Group: M.M. Kelly, Members of the Working Group:, V. Keatings, R. Leigh, C. Peterson, J. Shute, P. Venge, and R. Djukanovic Analysis of fluid{-}phase mediators Eur. Respir. J., July 1, 2002; 20(37_suppl): 24S - 39s. [Full Text] [PDF]

				A.W.A. Kamps, M.J. Visser, T.W. de Vries, W.M.C. van Aalderen, D.S. Postma, and P.L.P. Brand The feasibility of airways hyperresponsiveness as an inclusion criterion for studies on childhood asthma Eur. Respir. J., May 1, 2001; 17(5): 887 - 891. [Abstract] [Full Text] [PDF]

				J. D. LEUPPI, C. M. SALOME, C. R. JENKINS, S. D. ANDERSON, W. XUAN, G. B. MARKS, H. KOSKELA, J. D. BRANNAN, R. FREED, M. ANDERSSON, et al. Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 406 - 412. [Abstract] [Full Text]